Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Endometriosis Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Hormonal Therapy
  • 1.3.3 Add-back Medication
  • 1.3.4 Progestogens
  • 1.3.5 Chinese Herbs
• 1.4 Market Segment by Application
  • 1.4.1 Global Endometriosis Drugs Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Clinics
  • 1.4.4 Research Institutes
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Endometriosis Drugs Market Size
  • 2.1.1 Global Endometriosis Drugs Revenue 2014-2025
  • 2.1.2 Global Endometriosis Drugs Sales 2014-2025
• 2.2 Endometriosis Drugs Growth Rate by Regions
  • 2.2.1 Global Endometriosis Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Endometriosis Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Endometriosis Drugs Sales by Manufacturers
  • 3.1.1 Endometriosis Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Endometriosis Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Endometriosis Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Endometriosis Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Endometriosis Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Endometriosis Drugs Price by Manufacturers
• 3.4 Key Manufacturers Endometriosis Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Endometriosis Drugs Market
• 3.6 Key Manufacturers Endometriosis Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Hormonal Therapy Sales and Revenue (2014-2019)
  • 4.1.2 Add-back Medication Sales and Revenue (2014-2019)
  • 4.1.3 Progestogens Sales and Revenue (2014-2019)
  • 4.1.4 Chinese Herbs Sales and Revenue (2014-2019)
• 4.2 Global Endometriosis Drugs Sales Market Share by Type
• 4.3 Global Endometriosis Drugs Revenue Market Share by Type
• 4.4 Endometriosis Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Endometriosis Drugs Sales by Application

6 United States

• 6.1 United States Endometriosis Drugs Breakdown Data by Company
• 6.2 United States Endometriosis Drugs Breakdown Data by Type
• 6.3 United States Endometriosis Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Endometriosis Drugs Breakdown Data by Company
• 7.2 European Union Endometriosis Drugs Breakdown Data by Type
• 7.3 European Union Endometriosis Drugs Breakdown Data by Application

8 China

• 8.1 China Endometriosis Drugs Breakdown Data by Company
• 8.2 China Endometriosis Drugs Breakdown Data by Type
• 8.3 China Endometriosis Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Endometriosis Drugs Breakdown Data by Company
• 9.2 Rest of World Endometriosis Drugs Breakdown Data by Type
• 9.3 Rest of World Endometriosis Drugs Breakdown Data by Application
• 9.4 Rest of World Endometriosis Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Endometriosis Drugs Sales by Countries
  • 9.4.2 Rest of World Endometriosis Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 AbbVie
  • 10.1.1 AbbVie Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.1.4 Endometriosis Drugs Product Introduction
  • 10.1.5 AbbVie Recent Development
• 10.2 Astellas Pharma
  • 10.2.1 Astellas Pharma Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.2.4 Endometriosis Drugs Product Introduction
  • 10.2.5 Astellas Pharma Recent Development
• 10.3 AstraZeneca
  • 10.3.1 AstraZeneca Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.3.4 Endometriosis Drugs Product Introduction
  • 10.3.5 AstraZeneca Recent Development
• 10.4 Debiopharm Group
  • 10.4.1 Debiopharm Group Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.4.4 Endometriosis Drugs Product Introduction
  • 10.4.5 Debiopharm Group Recent Development
• 10.5 Evotec AG
  • 10.5.1 Evotec AG Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.5.4 Endometriosis Drugs Product Introduction
  • 10.5.5 Evotec AG Recent Development
• 10.6 Kissei Pharmaceutical
  • 10.6.1 Kissei Pharmaceutical Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.6.4 Endometriosis Drugs Product Introduction
  • 10.6.5 Kissei Pharmaceutical Recent Development
• 10.7 Neurocrine Biosciences
  • 10.7.1 Neurocrine Biosciences Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.7.4 Endometriosis Drugs Product Introduction
  • 10.7.5 Neurocrine Biosciences Recent Development
• 10.8 ObsEva
  • 10.8.1 ObsEva Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.8.4 Endometriosis Drugs Product Introduction
  • 10.8.5 ObsEva Recent Development
• 10.9 Pfizer
  • 10.9.1 Pfizer Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.9.4 Endometriosis Drugs Product Introduction
  • 10.9.5 Pfizer Recent Development
• 10.10 Repros Therapeutics
  • 10.10.1 Repros Therapeutics Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Endometriosis Drugs
  • 10.10.4 Endometriosis Drugs Product Introduction
  • 10.10.5 Repros Therapeutics Recent Development
• 10.11 Roivant Sciences GmbH
• 10.12 Takeda Pharmaceutical Company Limited
• 10.13 ValiRx

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Endometriosis Drugs Sales Channels
  • 11.2.2 Endometriosis Drugs Distributors
• 11.3 Endometriosis Drugs Customers

12 Market Forecast

• 12.1 Global Endometriosis Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Endometriosis Drugs Sales Forecast by Type
• 12.3 Global Endometriosis Drugs Sales Forecast by Application
• 12.4 Endometriosis Drugs Forecast by Regions
  • 12.4.1 Global Endometriosis Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Endometriosis Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Endometriosis affects an estimated 1 in 10 women in the reproductive age group of 15-49 years.
Among these therapies, Elagolix, a first-in-class GnRH receptor antagonist, is closest to market.
In 2019, the market size of Endometriosis Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Endometriosis Drugs.

This report studies the global market size of Endometriosis Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Endometriosis Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
AbbVie
Astellas Pharma
AstraZeneca
Debiopharm Group
Evotec AG
Kissei Pharmaceutical
Neurocrine Biosciences
ObsEva
Pfizer
Repros Therapeutics
Roivant Sciences GmbH
Takeda Pharmaceutical Company Limited
ValiRx

Market Segment by Product Type
Hormonal Therapy
Add-back Medication
Progestogens
Chinese Herbs

Market Segment by Application
Hospitals
Clinics
Research Institutes

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Endometriosis Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Endometriosis Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Endometriosis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025